Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Oesophagogastric Cancer × Epirubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 180 Stomach Neoplasms 29 Triple Negative Breast Neoplasms 27 Inflammatory Breast Neoplasms 18 Esophageal Neoplasms 14 Carcinoma, Hepatocellular 14 Lymphoma, Large B-Cell, Diffuse 8 Sarcoma 7 Neoplasms 6 Non-Muscle Invasive Bladder Neoplasms 5 Urinary Bladder Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Liver Neoplasms 4 Testicular Neoplasms 3 Primary Breast Cancer 3 Pathologic Complete Response 3 Lymphoma 3 Gallbladder Neoplasms 3 Carcinoma, Ductal, Breast 3 Breast Neoplasms, Male 3 Adenocarcinoma Of Esophagus 3 Unspecified Adult Solid Tumor, Protocol Specific 2 Recurrence 2 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Osteosarcoma 2 Neoplasms, Germ Cell and Embryonal 2 Neoplasm Metastasis 2 Lymphoma, T-Cell, Peripheral 2

Interventions

Neoadjuvant Therapy 1 Lapatinib 1 Epirubicin 1 Cisplatin 1 Chemotherapy, Adjuvant 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00450203 2016-12-01

ST03

Medical Research Council

Phase 2/3 Unknown

Gastrointestinal

Oesophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡